Isotopen Technologien München: Funding, Investors & Team (Sep 2026)
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
Isotopen Technologien München has raised $66.8M across 2 funding rounds on record, the most recent a Private Equity of $36.4M announced in Mar 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Isotopen Technologien München Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Isotopen Technologien München Funding Rounds
Isotopen Technologien München raised $30.4M in an undisclosed round announced in Jun 2021.
9 months later, a Private Equity of $36.4M was announced in Mar 2022.
Isotopen Technologien München Founders and Leadership Team
Contact details for the Isotopen Technologien München team: 1 of 1 has an email address on file.
Start 14-day free trial →Isotopen Technologien München Funding Compared to Other Biotechnology Startups
Isotopen Technologien München's latest round of $36.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Isotopen Technologien München in Biotechnology and Garching
Companies Similar to Isotopen Technologien München
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Isotopen Technologien München Funding FAQs
What does Isotopen Technologien München do?
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
How much funding has Isotopen Technologien München raised?
Isotopen Technologien München has raised $66.8M across 2 rounds on record. The most recent is a Private Equity of $36.4M announced in Mar 2022.
When did Isotopen Technologien München last raise funding?
Isotopen Technologien München's most recent funding round on record is a Private Equity of $36.4M, announced in Mar 2022.
Who is the CEO of Isotopen Technologien München?
Steffen Schuster is listed as CEO at Isotopen Technologien München.
Where is Isotopen Technologien München headquartered?
Isotopen Technologien München is based in Garching, Bayern, Germany.
How many employees does Isotopen Technologien München have?
Isotopen Technologien München is in the 101-250 employee band.
How does Isotopen Technologien München's funding compare to other Biotechnology startups?
Isotopen Technologien München's latest round of $36.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Isotopen Technologien München Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Isotopen Technologien München is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.